Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
Leukemia ( IF 12.8 ) Pub Date : 2019-12-11 , DOI: 10.1038/s41375-019-0658-7 Simon A Rule 1 , Guillaume Cartron 2 , Christopher Fegan 3 , Franck Morschhauser 4, 5 , Lingling Han 6 , Siddhartha Mitra 6 , Gilles Salles 7 , Martin J S Dyer 8
中文翻译:
使用选择性布鲁顿酪氨酸激酶抑制剂替拉鲁替尼(GS / ONO-4059)治疗的套细胞淋巴瘤(MCL)患者的长期随访。
更新日期:2019-12-11
Leukemia ( IF 12.8 ) Pub Date : 2019-12-11 , DOI: 10.1038/s41375-019-0658-7 Simon A Rule 1 , Guillaume Cartron 2 , Christopher Fegan 3 , Franck Morschhauser 4, 5 , Lingling Han 6 , Siddhartha Mitra 6 , Gilles Salles 7 , Martin J S Dyer 8
Affiliation
中文翻译:
使用选择性布鲁顿酪氨酸激酶抑制剂替拉鲁替尼(GS / ONO-4059)治疗的套细胞淋巴瘤(MCL)患者的长期随访。